StageUnattributed VC | Alive
About Beta-O2 Technologies
Beta-O2 Technologies is a biomedical company developing a proprietary implantable bioreactor, the ßAir. The company's flagship product is called the ßAir Bio-artificial Pancreas. It is in development as a treatment and potential cure for type 1 diabetes (T1D). ßAir was first designed to address the main problems of the otherwise successful procedures in which islets of Langerhans (i.e. pancreatic endocrine cells) are transplanted in diabetic patients, such as the need for life-long immunosuppressive pharmacological treatment and limited functionality of the transplanted islets over time due to an insufficient oxygen supply. The company's second pipeline product is the ßAir Bio-artificial Adrenal for the treatment of adrenocortical insufficiency and other stress-related disorders. This product is currently at the pre-clinical stage of development.
Missing: Beta-O2 Technologies's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Beta-O2 Technologies's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Beta-O2 Technologies
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Beta-O2 Technologies is included in 3 Expert Collections, including Medical Devices.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Beta-O2 Technologies Patents
Beta-O2 Technologies has filed 20 patents.
The 3 most popular patent topics include:
- Implants (medicine)
- Blood tests
- Cell biology
Diabetes, Sensors, Industrial gases, Biotechnology, Implants (medicine)
Diabetes, Sensors, Industrial gases, Biotechnology, Implants (medicine)
Latest Beta-O2 Technologies News
Apr 26, 2018
MIT researchers develop implantable device to enhance type 1 diabetes treatment Researchers from the Massachusetts Institute of Technology (MIT) have worked with Beta-O2 Technologies to develop an implantable device, which could help insulin-producing cells live longer after transplant and improve treatment of type 1 diabetes. The partnership has tested an implantable device, which renders islet cells with their own supply of oxygen through chamber that can be refilled every 24 hours, helping to improve treatment of type 1 diabetes. Islet cells are pancreatic cells, which are responsible for producing insulin when blood glucose concentration increases. MIT professor of chemical engineering and study senior author Clark Colton said: “The benefits of this approach are: you keep the islets alive to perform their function, you don’t need as much tissue, and you reduce the ability of the implants to provoke an immune response.” Tests of the implants in rats demonstrated that around 90% of the islets stayed viable for several months, and most of the rats continued to have normal blood glucose levels across the process. The destruction of pancreas’ islet cells by the patient’s own immune system results in type 1 diabetes. To offer protection for the transplanted cells, researchers are working on the development of implants that can encapsulate islets in a material such as a polymer. Islets are encapsulated in a slab of alginate in the device tested by the researchers. Alginate is a polysaccharide produced by algae, which is having about 600μ thickness. A membrane on one side of slab excludes immune cells and large proteins, and allows to pass insulin, nutrients, and oxygen. With about 5mm thick, the gas chamber below the chamber carries atmospheric gases such as nitrogen and carbon dioxide, as well as oxygen. Oxygen flows from the chamber over the semipermeable membrane, and into the islets engrafted in the alginate slab. The oxygen partial pressure continually drops, as it diffuses through the slab. Researchers determined that they require to start with an oxygen partial pressure of 500 mm Hg in the gas chamber to assure that that the partial pressure remains at least 50 mm Hg for 24 hours After 24 hours, the oxygen will be refilled through a port, in which a device implanted under the skin and connected to a catheter that leads to the encapsulated islets. Researchers demonstrated that around 90% of the islets survived the entire transplant period, which ranged from 11 weeks to eight months, in tests in diabetic mice without immunosuppression. Image: Illustration showing pancreatic islets and oxygen molecules. Photo: courtesy of Christine Daniloff/MIT. Share: Latest News
Beta-O2 Technologies Frequently Asked Questions (FAQ)
When was Beta-O2 Technologies founded?
Beta-O2 Technologies was founded in 1999.
Where is Beta-O2 Technologies's headquarters?
Beta-O2 Technologies's headquarters is located at 11 Amal St, Rosh HaAyin.
What is Beta-O2 Technologies's latest funding round?
Beta-O2 Technologies's latest funding round is Unattributed VC.
How much did Beta-O2 Technologies raise?
Beta-O2 Technologies raised a total of $1M.
Who are the investors of Beta-O2 Technologies?
Investors of Beta-O2 Technologies include Sherpa InnoVentures, Juvenile Diabetes Research Foundation, Aurum Ventures, Pitango Venture Capital, GlenRock Israel and 4 more.
Who are Beta-O2 Technologies's competitors?
Competitors of Beta-O2 Technologies include CeQur, Mercator MedSystems, Synapse Biomedical, eNeura Therapeutics, Cianna Medical and 11 more.
Compare Beta-O2 Technologies to Competitors
Pulse Metric designs, manufactures and markets products and services that transform a simple blood pressure reading into a powerful functional profile of the patients cardiovascular system, including cardiac output, vessel compliance, vascular resistance and left ventricular contractility. Within a minute of uploading a DynaPulse blood pressure waveform to the DynaPulse Analysis Center website, 17 hemodynamic parameters are calculated, displayed and trended, providing clinicians with numeric values profiling the hearts pumping performance, blood vessel elasticity and vascular resistance, against normative ranges.The company believes the simplicity of its methodology and the significance of the information provided to the physician will improve quality of care while reducing costs. Pulse Metric has been granted nine patents in support of its proprietary technology.
Neuromonics is an Australian company that has developed an FDA approved device for treatment of tinnitus over a six month process with 2 hours of use per day.
Valor Medical is a San Diego-based medical device company that has developed liquid embrolic technology for the treatment of cerebral aneurysms.
Linguaflex is a medical device company with a patent pending technology to treat obstructive sleep apnea. LinguaFlex's LTR is implanted and designed to be comfortable, therefore addressing the lack of compliance as an issue in the successful treatment of OSA.
Apneon is an early stage medical device company developing devices for the treatment of sleep apnea.
MetaCure is a clinical-stage device company focused on the treatment of adult type II diabetes via an implantable pulse generator delivering electrical stimulation via gastric contractility modulation.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.